Moderna (MRNA)

Healthcare · Biotechnology · S&P 500
$187.46 -7.75% on the day Market cap $67.4B 52-week range $22.28 to $212.22 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Moderna's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

F

Five factors scored 1 to 9 from MRNA's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation1
Profitability0
Growth3
Financial health6
Cash efficiency0

Key numbers

P/E (trailing)—
P/E (forward)85.7x
Price / free cash flow—
EV / EBITDA—
Price / sales30.3x
Price / book10.8x
Revenue growth+2.1%
Operating margin-149.0%
Net margin-141.4%
Return on equity-46.6%
Dividend yield—
Debt / equity0.62x

Results from SEC filings

Fiscal years, from Moderna's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$18.5B$19.3B$6.8B$3.2B$1.9B
Net income$12.2B$8.4B-$4.7B-$3.6B-$2.8B
Free cash flow$13.3B$4.6B-$3.8B-$4.1B-$2.1B
EPS (diluted)$28.29$20.12-$12.33-$9.28-$7.26
Operating margin72.0%48.9%-61.9%-121.9%-158.1%

Where the revenue comes from

Revenue by products, fiscal 2025.

Net product sales$1.8B94%
Other revenue$126M6%

Superinvestors who own MRNA

From each investor's latest 13F filing (what a 13F shows). 2 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Ron Baron
Baron Capital (BAMCO)
New position $139M0.21%Q2 2026
Cliff Asness
AQR Capital Management
Added $34M0.01%Q2 2026

Insider buying

Open-market purchases by Moderna's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

DateInsiderSharesPriceValue
Jan 23, 2026 Ro Khanna
0$48.78—
Jan 23, 2026 Ro Khanna
0$48.78—

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when MRNA trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Moderna insiders buying the stock?

2 open-market insider purchases of MRNA in the last 12 months, from SEC Form 4 filings.

Which superinvestors own Moderna?

2 of the superinvestors Investingly tracks hold MRNA in their latest 13F, including Ron Baron, Cliff Asness.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.